Atlas Trials

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Clinical trial NCT05957510 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05957510
Sponsor
Guangdong Association of Clinical Trials
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Small-cell Lung Cancer
Start date
2023-07-07
Primary completion
2026-07-02
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.